summary slide.png (128.67 kB)

Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results From a Phase 2 Open-Label Extension Trial

media

posted on 26.01.2021, 16:59 by Adis journals on behalf of, Kim A. Papp, Saskia de Vente, Jiewei Zeng, Mary Flack, Byron Padilla, Stephen K. Tyring

Article full text

The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

History

References

https://link.springer.com/article/10.1007/s13555-021-00490-3

Usage metrics

Read the peer-reviewed publication

Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results From a Phase 2 Open-Label Extension Trial

Dermatology and Therapy

Keywords

Biologic therapy Interleukin-23 Open-label extension Psoriasis Risankizumab

Licence

CC BY-NC 4.0

Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results From a Phase 2 Open-Label Extension Trial

History

References

Usage metrics

Read the peer-reviewed publication

Categories

Keywords

Licence

Exports